Energetically inefficient inter‐organ substrate shuttles are proposed contributors to cachexia‐related weight loss. Here, we examined glycolytic pathway metabolites, enzyme activity and transport proteins in skeletal muscle, liver and tumours of mice with cachexia‐related weight loss induced by colon‐26 cancer cells. Skeletal muscle of cachexic mice had increased [L‐lactate]/[pyruvate], LDH activity and lactate transporter MCT1. Cachexic livers also showed increased MCT1. This is consistent with the proposal that the rate of muscle‐derived lactate shuttling to liver for use in gluconeogenesis is increased, that is, an increased Cori cycle flux in weight‐losing cachexic mice. A second shuttle between liver and tumour may also contribute to disrupted energy balance and weight loss. We found increased high‐affinity glucose transporter GLUT1 in tumours, suggesting active glucose uptake, tumour MCT1 detection and decreased intratumour [L‐lactate]/[pyruvate], implying increased lactate efflux and/or intratumour lactate oxidation. Last, high [L‐lactate]/[pyruvate] and MCT1 in cachexic muscle provides a potential muscle‐derived lactate supply for the tumour (a ‘reverse Warburg effect’), supporting tumour growth and consequent cachexia. Our findings suggest several substrate shuttles among liver, skeletal muscle and tumour contribute to metabolic disruption and weight loss. Therapies that aim to normalize dysregulated substrate shuttling among energy‐regulating tissues may alleviate unintended weight loss in cancer cachexia.
Significance of the study
Cachexia is a serious complication of cancer characterized by severe weight loss, muscle atrophy and frailty. Cachexia occurs in roughly half of all cancer patients, and in up to 80% of patients with advanced disease. Cachexia independently worsens patient prognosis, lowers treatment efficacy, increases hospitalization cost and length of stay, and accounts for 20‐30% of cancer‐related deaths. There are no effective treatments. Our findings suggest several substrate shuttles among liver, skeletal muscle and tumour contribute to metabolic disruption and weight loss in cancer cachexia. Identifying therapies that normalize dysregulated substrate shuttling among energy‐regulating tissues may protect against cachexia‐related weight loss.